Moderna Reports Results of COVID-19 Vaccine in P-II/III KidCOVE Study for the Treatment of COVID-19

October 26, 2021 Auto Bot Clinical Trials, Covid-19 Vaccine, Moderna, mRNA-1273, P-II/III 0

Shots:

  • The P-II/III KidCOVE study evaluated the safety, tolerability, reactogenicity & effectivity of mRNA-1273 in 4753 children aged 6-12yrs. with COVID-19, administered as 28 days apart
  • The study met its primary immunogenicity EPs & interim analysis showed a robust neutralizing Ab response after two 50 μg doses of mRNA-1273. The therapy was well tolerated with a safety & tolerability profile that was consistent with the P-III COVE study in adolescents & adults
  • Additionally, all participants will be monitored for 12mos. after the 2nd dose to evaluate the long-term protection & safety. The company plans to submit the data to the US FDA, EMA, and other global regulatory imminently

Click here ­to­ read full press release/ article | Ref: Moderna | Image: The Indian Express

The post Moderna Reports Results of COVID-19 Vaccine in P-II/III KidCOVE Study for the Treatment of COVID-19 first appeared on PharmaShots.